Incyte Corp

Common Name

Incyte

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

2,617

Ticker

INCY

Exchange

NASDAQ/NGS

Website

www.incyte.com

Description

Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to a... Show more

Financial Statements of Incyte

Below are the financial statements of Incyte, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	1,687.83^a	3,213.38^a
Marketable securities - available-for-sale	470.26^a	442.67^a
Accounts receivable	853.15^a	743.56^a
Inventory	58.87^a	62.97^a
Prepaid expenses and other current assets	168.91^a	182.83^a
Total current assets	3,239.03^a	4,645.4^a
Assets	—	—
Restricted cash	1.62^a	1.85^a
Long term equity investments	18.81^a	187.72^a
Inventory	348.33^a	206.97^a
Property and equipment, net	763.41^a	751.51^a
Finance lease right-of-use assets, net	30.8^a	25.54^a
Other intangible assets, net	113.8^a	123.55^a
Goodwill	155.59^a	155.59^a
Deferred income tax asset	762.07^a	631.89^a
Other assets, net	10.85^a	52.11^a
Total assets	5,444.32^a	6,782.11^a
Current liabilities	—	—
Accounts payable	197.47^a	109.6^a
Accrued compensation	188.68^a	153.35^a
Accrued and other current liabilities	1,212.05^a	935.57^a
Finance lease liabilities	4.42^a	3.44^a
Acquisition-related contingent consideration	39.24^a	38.42^a
Total current liabilities	1,641.85^a	1,240.38^a
Liabilities and stockholders’ equity	—	—
Acquisition-related contingent consideration	153.76^a	173.58^a
Finance lease liabilities	33.54^a	29.16^a
Other liabilities	167.54^a	149.15^a
Total liabilities	1,996.69^a	1,592.27^a
Stockholders’ equity	—	—
Preferred stock, $0.001 par value	0^a	0^a
Common stock, $0.001 par value	0.19^a	0.22^a
Additional paid-in capital	4,533.44^a	5,016.12^a
Accumulated other comprehensive (loss) income	-13.12^a	13.11^a
(Accumulated deficit) retained earnings	-1,072.88^a	160.39^a
Total stockholders’ equity	3,447.63^a	5,189.84^a
Total liabilities and stockholders’ equity	5,444.32^a	6,782.11^a

Verified Sources Behind Incyte’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Incyte’s data sources below and access millions more through our Disclosure Search.

a. Incyte's 10-K 2024

Trace every data point back to Incyte’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Incyte Corp

Financial Statements of Incyte

Verified Sources Behind Incyte’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Royalty Pharma PLC

Insmed Inc

Blueprint Medicines Corp

Immunovant Inc

Ultragenyx Pharmaceutical Inc

Cytokinetics Inc